David Steensma

David Steensma is Chief Medical Officer of Ajax Therapeutics and previously was Global Head of Hematology for Novartis. Prior to 2021, he was an academic hematologist with a clinical and research focus on myeloid neoplasms and clonal hematopoiesis, and served as Edward P. Evans Chair in MDS at Dana-Farber Cancer Institute.